皮肤病专科医院电子病历的设计与应用

???????目的 研究与开发具有皮肤病专科特色的电子病历系统,以实现皮肤科病人医疗信息的采集、加工、存储、传输和服务。方法 以windows sqlserver2005为后台数据库,以XML、C#为开发语言,建立皮肤病结构化病历。结果 该系统运行良好,安全稳定、易维护、通用性好。有效地提高了医生书写病历的速度和质量,并具有皮疹数码照片嵌入等功能。结论 本研究实现了具有皮肤病专科特色的电子病历系统,值得皮肤病医院推荐使用。     

试析围手术期安全管理的切入点

通过建立信息技术控制体系和JCI标准下管理制度保障体系,不断优化工作流程,强化质量监控部门管理职能,定期开展临床技能培训,能够实现围手术期患者安全目标。     

黑龙江省县级综合医院绩效评价实证研究

目的 构建县级综合医院快速绩效评价工具,为改善县医院绩效管理提供依据。方法 应用专题小组法和专家咨询法,筛选关键指标构成快速绩效评价指标体系,采用直接评分法和TOPSIS法计算各医院的绩效综合评价结果。结果 工作质量方面的短板、较低的基本药物配备率和薄弱的人力资源管理是各医院的共性问题。医院费用控制及经济管理维度中的关键政策指标达标率在各医院间波动较大。结论 开发的县级医院快速绩效评价工具具有一定的科学性和可行性。     

标准操作流程模型在医疗设备管理流程中的应用

依据标准操作流程模型,将医疗设备管理细分为物流采购控制、应用核算控制和质量技术控制3个方面,实施了医院医疗设备管理的标准化和一些有效的做法, 阐述了加强医疗设备标准化管理的必要性, 提出了建立医疗设备质量管理体系的理念,使医疗设备管理逐步进入质量—效率—效益良性循环的发展轨道。

     

医院床位利用效率评价比较及影响因素分析

通过对国内外床位利用效率评价方法、评价结果的现状分析,总结归纳床位利用效率的影响因素,发现影响床位利用效率的因素主要有国家相关政策、医院自身管理和医护人员行为、病人病种结构及其他不可控因素,国内对床位利用效率的评价研究存在方法单一、影响因素分析不够透彻以及政策建议缺乏针对性和可操作性等几个方面的问题。      

黑龙江省县级医院绩效评价指标体系构建研究

目的 构建适用于黑龙江省县级医院的绩效评价模型和指标体系,为县级医院开展绩效评价、改善绩效管理提供决策参考。方法 应用文献分析法和专题小组讨论法构建评价模型和初始指标库,运用专家咨询法筛选评价指标并确定指标权重。结果 运用关键绩效指标理念构建了以工作质量、工作效率、医疗费用、综合管理及满意度评价为核心维度的县级医院绩效评价模型及指标体系。结论 指标体系的可信程度较高,能有效反映县级医院绩效管理的核心环节。     

公立医疗机构公益性评价方法初探

????? 目的 探索公立医疗机构公益性评价的方法。方法 采用涵盖公平性与可及性、适宜性、质量和效率4个维度的18个指标,应用秩和比法、TOPSIS法和效度系数法对某市10家公立医院的公益性进行分析,用Kendall’s W协同系数检验对3种评价方法的结果的一致性进行检验。结果 3种评价方法都可以用于医疗机构公益性评价,Kendall’s W协同系数检验的结果说明3种评级方法具有很好的一致性。结论 3种方法各有利弊,可以运用多种方法评价公立医疗机构的公益性,数据的可得性成为公立医疗机构机构公益性评价的重要制约因素。

     

某大型医院专利管理状况调查与分析

目的 为进一步了解医院专利管理现状,发现专利管理存在的问题,并探讨对策。 方法 对医院200名科技人员进行专利基本知识和专利管理情况随机问卷调查和统计分析。结果 发现科技人员对专利基本知识掌握比例不高,重点是可申请专利内容、职务发明创造的界定以及发明人权利;科技人员专利转化的积极性和能力不足,经费、转化渠道、时间是影响专利维持、转让的重要因素。 结论 提示医院应进一步加强专利知识的普及,专利申请的监管、有效专利的动态评估和专利成果的转化实施。

     

Nexadia数据管理系统应用的前期论证

通过对以往血液透析中心的手工管理模式缺陷的分析,重点介绍Nexadia数据管理系统的基本功能和特点,并积极探索其应用于血液净化中心日常工作所发挥的积极作用。

     

公立医院管办分开改革试点情况对比分析

随着《关于公立医院改革试点的指导意见》的出台,探索管办分开的有效形式成为公立医院改革的一项重要任务。北京的“管办分开不分家”和上海的“管办分开又分家”两种管办分开改革试点有诸多相同点和不同点,各有优势、劣势、机遇、挑战。通过SWOT法,对比分析北京、上海两地的管办分开改革举措,以期为公立医院改革试点提供理论支持与决策参考。

     

大医院“直管”社区卫生服务机构转诊模式实施效果评价

目的 评价武汉市大医院“直管”社区卫生服务机构转诊模式的实施效果。 方法 通过对转诊组与非转诊组各200例患者进行对照比较分析,从治疗效果、治疗费用及费用构成等方面进行评价。 结果 “直管”项目有效促进了社区与大医院之间双向转诊的开展,减少了患者住院天数与住院费用。结论 建议明确界定“直管”模式的政策定义、加快建设区域信息网络共享机制和加大政府医疗保险政策的支持力度,从而进一步发挥“直管”项目在促进双向转诊上的作用。     

Efficacy and safety of AZD3199 vs formoterol in COPD: a randomized,double-blind study

Background

We investigated the efficacy and safety of AZD3199, a novel inhaled ultra-LABA, with the main aim of establishing a dose that would maintain 24-hour bronchodilation in patients with COPD.

Methods

Patients (n = 329) were randomized to AZD3199 (200, 400 or 800 μg o.d.), formoterol (9 μg b.i.d.) or placebo via Turbuhaler® in a parallel group study. The primary objective of the study was to compare the clinical efficacy of three doses of AZD3199 inhaled once daily with 9 μg formoterol twice daily and placebo, over a 4-week treatment period in adults with moderate-to-severe COPD. After 4 weeks, peak (0–4 h) and trough (24–26 h) forced expiratory volume in 1 second (FEV₁) were assessed as the primary efficacy outcome variables.

Results

All AZD3199 doses significantly increased mean peak and trough FEV₁ versus placebo (106–171 ml and 97–110 ml increases, respectively), but with no clear dose–response; the level of bronchodilation was comparable to or greater than that achieved with formoterol. Forced vital capacity (FVC) at peak bronchodilation also significantly increased with AZD3199 versus placebo (153–204 ml). COPD symptom scores and reliever use were reduced with AZD3199, while FEV₁ reversibility was unaltered. Adverse events were mild-to-moderate, with no safety concerns identified. Drug exposure was dose-proportional, but lower than predicted from healthy volunteers.

Conclusions

All three doses of AZD3199 produced 24-hour bronchodilation, but with no clear dose–response, suggesting that doses of 200 μg or less may be sufficient to maintain bronchodilation over 24 hours in patients with COPD. No safety concerns were identified. Further studies are required to determine the once-daily AZD3199 dose for COPD.

Trial registration

Clinicaltrials.gov, {"type":"clinical-trial","attrs":{"text":"NCT00929708","term_id":"NCT00929708"}}NCT00929708     

Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens

Objectives

Muckle-Wells syndrome (MWS) is an autoinflammatory disease characterized by excessive interleukin-1 (IL-1) release, resulting in recurrent fevers, sensorineural hearing loss, and amyloidosis. IL-1 inhibition with anakinra, an IL-1 receptor antagonist, improves clinical symptoms and inflammatory markers. Subclinical disease activity is commonly observed. Canakinumab, a fully human IgG1 anti-IL-1β monoclonal antibody, can abolish excess IL-1β. The study aim was to analyze the efficacy and safety of these two anti-IL-1 therapies.

Methods

Two cohorts of patients with severe MWS and confirmed NLRP3 mutation were treated with anakinra and/or canakinumab. Clinical and laboratory features including ESR, CRP, SAA, and the neutrophil marker S100A12 were determined serially. Disease activity was captured by MWS disease activity scores (MWS-DAS). Remission was defined as MWS-DAS ≤5 plus normal CRP and SAA. Treatment efficacy and safety were analyzed.

Results

The study included 12 anakinra- and 14 canakinumab-treated patients; the median age was 33.5 years (3.0 years to 72.0 years); 57% were female patients. Both treatment regimens led to a significant reduction of clinical disease activity and inflammatory markers. At last follow-up, 75% of anakinra-treated and 93% of canakinumab-treated patients achieved remission. During follow-up, S100A12 levels mirrored recurrence of disease activity. Both treatment regimens had favorable safety profiles.

Conclusions

IL-1 blockade is an effective and safe treatment in MWS patients. MWS-DAS in combination with MWS inflammatory markers provides an excellent monitoring tool set. Canakinumab led to a sustained control of disease activity even after secondary failure of anakinra therapy. S100A12 may be a sensitive marker to detect subclinical disease activity.     

Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week,randomized, double-blind,placebo-controlled study

Background

The long-acting muscarinic antagonist (LAMA) umeclidinium (UMEC) and the combination of UMEC with the long-acting β₂-agonist (LABA) vilanterol (UMEC/VI) are approved maintenance treatments for chronic obstructive pulmonary disease (COPD) in the US and EU. They are not indicated for the treatment of asthma.

Methods

In this 52-week, double-blind, placebo-controlled, parallel-group safety study (GSK study DB2113359; {"type":"clinical-trial","attrs":{"text":"NCT01316887","term_id":"NCT01316887"}}NCT01316887), patients were randomized 2:2:1 to UMEC/VI 125/25 mcg, UMEC 125 mcg, or placebo. Study endpoints included adverse events (AEs), clinical chemistry and hematology parameters, vital signs, 12-lead, and 24-hour Holter electrocardiograms. COPD exacerbations and rescue medication use were assessed as safety parameters; lung function was also evaluated.

Results

The incidence of on-treatment AEs, serious AEs (SAEs), and drug-related AEs was similar between treatment groups (AEs: 52–58%; SAEs: 6–7%; drug-related AEs: 12–13%). Headache was the most common AE in each treatment group (8–11%). AEs associated with the LAMA and LABA pharmacologic classes occurred at a low incidence across treatment groups. No clinically meaningful effects on vital signs or laboratory assessments were reported for active treatments versus placebo. The incidences of atrial arrhythmias with UMEC/VI 125/25 mcg were similar to placebo; for UMEC 125 mcg, the incidences of ectopic supraventricular beats, sustained supraventricular tachycardia, and ectopic supraventricular rhythm were ≥2% greater than placebo. With active treatments, COPD exacerbations were fewer (13–15% of patients reporting ≥1 exacerbation) and on average less rescue medication was required (1.6–2.2 puffs/day) versus placebo (24% reporting ≥1 exacerbation, 2.6 puffs/day). Both active treatments improved lung function versus placebo.

Conclusion

UMEC/VI 125/25 mcg and UMEC 125 mcg were well tolerated over 12 months in patients with COPD.     

PATH模型对我国医院绩效评价体系构建的启示

绩效评价工具的选择对发挥医院绩效管理体系的作用和反映医院运营情况有着重要作用。本文简要介绍了医院质量改进的绩效评价工具（The Performance Assessment Tool For Quality Improvement In Hospitals,PATH）及其优势,提出我国医院绩效评价改革可以借鉴PATH模型,建立科学统一的指标评价体系,同时加快医疗领域信息化建设以及发挥第三方评价机构在医院绩效评价中的作用。     

Absence of mutations in GJB2 (Connexin-26) gene in an ethnic group of southwest Iran

BACKGROUND:

The common GJB2 gene mutation (35delG) has been previously reported from Iranian patients that were affected with nonsyndromic autosomal recessive deafness. We, therefore, for the first time, investigated the prevalence and frequency of the GJB2 gene mutation in the Iranian deaf population with Arabian origins.

MATERIALS AND METHODs:

We amplified and sequenced the entire coding sequence of the GJB2 gene from 61 deaf patients and 26 control subjects.

RESULT:

None of the analyzed samples revealed deafness-associated mutation.

CONCLUSION:

This finding differs from several reports from Iran as we have focused on the GJB2 gene that possesses various mutations as the cause of congenital recessive deafness.     

Reduction of surgical site infections after implementation of a bundle of care

Background

Surgical Site Infections (SSI) are relatively frequent complications after colorectal surgery and are associated with substantial morbidity and mortality.

Objective

Implementing a bundle of care and measuring the effects on the SSI rate.

Design

Prospective quasi experimental cohort study.

Methods

A prospective surveillance for SSI after colorectal surgery was performed in the Amphia Hospital, Breda, from January 1, 2008 until January 1, 2012. As part of a National patient safety initiative, a bundle of care consisting of 4 elements covering the surgical process was introduced in 2009. The elements of the bundle were perioperative antibiotic prophylaxis, hair removal before surgery, perioperative normothermia and discipline in the operating room. Bundle compliance was measured every 3 months in a random sample of surgical procedures.

Results

Bundle compliance improved significantly from an average of 10% in 2009 to 60% in 2011. 1537 colorectal procedures were performed during the study period and 300 SSI (19.5%) occurred. SSI were associated with a prolonged length of stay (mean additional length of stay 18 days) and a significantly higher 6 months mortality (Adjusted OR: 2.71, 95% confidence interval 1.76–4.18). Logistic regression showed a significant decrease of the SSI rate that paralleled the introduction of the bundle. The adjusted Odds ratio of the SSI rate was 36% lower in 2011 compared to 2008.

Conclusion

The implementation of the bundle was associated with improved compliance over time and a 36% reduction of the SSI rate after adjustment for confounders. This makes the bundle an important tool to improve patient safety.     

The effect of losartan therapy on ventricular function in Marfan patients with haploinsufficient or dominant negative <Emphasis Type="Italic">FBN1</Emphasis> mutations

Background

Mild biventricular dysfunction is often present in patients with Marfan syndrome. Losartan has been shown to reduce aortic dilatation in patients with Marfan syndrome. This study assesses the effect of losartan on ventricular volume and function in genetically classified subgroups of asymptomatic Marfan patients without significant valvular regurgitation.

Methods

In this predefined substudy of the COMPARE study, Marfan patients were classified based on the effect of their FBN1 mutation on fibrillin-1 protein, categorised as haploinsufficient or dominant negative. Patients were randomised to a daily dose of losartan 100 mg or no additional treatment. Ventricular volumes and function were measured by magnetic resonance imaging at baseline and after 3 years of follow-up.

Results

Changes in biventricular dimensions were assessed in 163 Marfan patients (48?% female; mean age 38 ± 13 years). In patients with a haploinsufficient FBN1 mutation (n = 43), losartan therapy (n = 19) increased both biventricular end diastolic volume (EDV) and stroke volume (SV) when compared with no additional losartan (n = 24): left ventricular EDV: 9 ± 26 ml vs. ?8 ± 24 ml, p = 0.035 and right ventricular EDV 12 ± 23 ml vs. ?18 ± 24 ml; p < 0.001 and for left ventricle SV: 6 ± 16 ml vs. ?8 ± 17 ml; p = 0.009 and right ventricle SV: 8 ± 16 ml vs. ?7 ± 19 ml; p = 0.009, respectively. No effect was observed in patients with a dominant negative FBN1 mutation (n = 92), or without an FBN1 mutation (n = 28).

Conclusion

Losartan therapy in haploinsufficient Marfan patients increases biventricular end diastolic volume and stroke volume, furthermore, losartan also appears to ameliorate biventricular filling properties.